vs
波士顿科学（BSX）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
波士顿科学的季度营收约是瑞思迈的3.7倍（$5.2B vs $1.4B），瑞思迈净利率更高（27.6% vs 25.7%，领先1.9%），波士顿科学同比增速更快（11.6% vs 11.0%），过去两年波士顿科学的营收复合增速更高（12.4% vs 9.0%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
BSX vs RMD — 直观对比
营收规模更大
BSX
是对方的3.7倍
$1.4B
营收增速更快
BSX
高出0.6%
11.0%
净利率更高
RMD
高出1.9%
25.7%
两年增速更快
BSX
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $1.4B |
| 净利润 | $1.3B | $392.6M |
| 毛利率 | 69.5% | 61.8% |
| 营业利润率 | — | 34.6% |
| 净利率 | 25.7% | 27.6% |
| 营收同比 | 11.6% | 11.0% |
| 净利润同比 | 99.0% | 13.9% |
| 每股收益（稀释后） | $0.90 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXRMD
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $1.4B | ||
| Q3 25 | $5.1B | $1.3B | ||
| Q2 25 | $5.1B | $1.3B | ||
| Q1 25 | $4.7B | $1.3B | ||
| Q4 24 | $4.6B | $1.3B | ||
| Q3 24 | $4.2B | $1.2B | ||
| Q2 24 | $4.1B | $1.2B |
净利润BSXRMD
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $392.6M | ||
| Q3 25 | $755.0M | $348.5M | ||
| Q2 25 | $795.0M | $379.7M | ||
| Q1 25 | $672.0M | $365.0M | ||
| Q4 24 | $563.0M | $344.6M | ||
| Q3 24 | $468.0M | $311.4M | ||
| Q2 24 | $322.0M | $292.2M |
毛利率BSXRMD
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | 61.8% | ||
| Q3 25 | 69.9% | 61.5% | ||
| Q2 25 | 67.7% | 60.8% | ||
| Q1 25 | 68.8% | 59.3% | ||
| Q4 24 | 67.8% | 58.6% | ||
| Q3 24 | 68.8% | 58.6% | ||
| Q2 24 | 69.2% | 58.5% |
营业利润率BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 34.6% | ||
| Q3 25 | 20.7% | 33.4% | ||
| Q2 25 | 16.2% | 33.7% | ||
| Q1 25 | 19.8% | 33.0% | ||
| Q4 24 | 14.8% | 32.5% | ||
| Q3 24 | 17.4% | 31.6% | ||
| Q2 24 | 12.6% | 31.2% |
净利率BSXRMD
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | 27.6% | ||
| Q3 25 | 14.9% | 26.1% | ||
| Q2 25 | 15.7% | 28.2% | ||
| Q1 25 | 14.4% | 28.3% | ||
| Q4 24 | 12.3% | 26.9% | ||
| Q3 24 | 11.1% | 25.4% | ||
| Q2 24 | 7.8% | 23.9% |
每股收益（稀释后）BSXRMD
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $2.68 | ||
| Q3 25 | $0.51 | $2.37 | ||
| Q2 25 | $0.53 | $2.58 | ||
| Q1 25 | $0.45 | $2.48 | ||
| Q4 24 | $0.38 | $2.34 | ||
| Q3 24 | $0.32 | $2.11 | ||
| Q2 24 | $0.22 | $1.97 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.4B |
| 总债务越低越好 | — | $403.9M |
| 股东权益账面价值 | — | $6.3B |
| 总资产 | — | $8.5B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $534.0M | $1.2B | ||
| Q1 25 | $725.0M | $932.7M | ||
| Q4 24 | $414.0M | $521.9M | ||
| Q3 24 | $2.5B | $426.4M | ||
| Q2 24 | $2.9B | $238.4M |
总债务BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | $403.9M | ||
| Q3 25 | $11.1B | $408.7M | ||
| Q2 25 | $11.1B | $658.4M | ||
| Q1 25 | $10.5B | $663.1M | ||
| Q4 24 | $9.0B | $662.9M | ||
| Q3 24 | $9.2B | $667.6M | ||
| Q2 24 | $9.0B | $697.3M |
股东权益BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $6.3B | ||
| Q3 25 | $23.4B | $6.1B | ||
| Q2 25 | $22.4B | $6.0B | ||
| Q1 25 | $22.2B | $5.5B | ||
| Q4 24 | $21.8B | $5.3B | ||
| Q3 24 | $20.7B | $5.2B | ||
| Q2 24 | $20.4B | $4.9B |
总资产BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $8.5B | ||
| Q3 25 | $42.7B | $8.3B | ||
| Q2 25 | $41.6B | $8.2B | ||
| Q1 25 | $40.1B | $7.6B | ||
| Q4 24 | $39.4B | $7.1B | ||
| Q3 24 | $38.1B | $7.2B | ||
| Q2 24 | $37.1B | $6.9B |
负债/权益比BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | 0.06× | ||
| Q3 25 | 0.48× | 0.07× | ||
| Q2 25 | 0.50× | 0.11× | ||
| Q1 25 | 0.47× | 0.12× | ||
| Q4 24 | 0.41× | 0.13× | ||
| Q3 24 | 0.45× | 0.13× | ||
| Q2 24 | 0.44× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $339.7M |
| 自由现金流经营现金流 - 资本支出 | — | $311.2M |
| 自由现金流率自由现金流/营收 | — | 21.9% |
| 资本支出强度资本支出/营收 | — | 2.0% |
| 现金转化率经营现金流/净利润 | — | 0.87× |
| 过去12个月自由现金流最近4个季度 | — | $1.8B |
8季度趋势，按日历期对齐
经营现金流BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $339.7M | ||
| Q3 25 | $1.3B | $457.3M | ||
| Q2 25 | $1.3B | $538.8M | ||
| Q1 25 | $541.0M | $578.7M | ||
| Q4 24 | $1.5B | $308.6M | ||
| Q3 24 | $1.0B | $325.5M | ||
| Q2 24 | $813.0M | $440.1M |
自由现金流BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $311.2M | ||
| Q3 25 | $1.2B | $414.4M | ||
| Q2 25 | $1.1B | $508.2M | ||
| Q1 25 | $354.0M | $557.9M | ||
| Q4 24 | $1.2B | $288.0M | ||
| Q3 24 | $823.0M | $307.7M | ||
| Q2 24 | $658.0M | $415.2M |
自由现金流率BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | 21.9% | ||
| Q3 25 | 22.9% | 31.0% | ||
| Q2 25 | 22.3% | 37.7% | ||
| Q1 25 | 7.6% | 43.2% | ||
| Q4 24 | 25.8% | 22.5% | ||
| Q3 24 | 19.6% | 25.1% | ||
| Q2 24 | 16.0% | 33.9% |
资本支出强度BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 2.0% | ||
| Q3 25 | 3.6% | 3.2% | ||
| Q2 25 | 3.1% | 2.3% | ||
| Q1 25 | 4.0% | 1.6% | ||
| Q4 24 | 6.1% | 1.6% | ||
| Q3 24 | 4.3% | 1.5% | ||
| Q2 24 | 3.8% | 2.0% |
现金转化率BSXRMD
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | 0.87× | ||
| Q3 25 | 1.78× | 1.31× | ||
| Q2 25 | 1.62× | 1.42× | ||
| Q1 25 | 0.81× | 1.59× | ||
| Q4 24 | 2.59× | 0.90× | ||
| Q3 24 | 2.14× | 1.05× | ||
| Q2 24 | 2.52× | 1.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
